Insight into Druckenmiller's Latest 13F Filings and Portfolio Adjustments. Stanley Druckenmiller (Trades, Portfolio), the ...

Ascendis Pharma (ASND) has released an update. Ascendis Pharma has released its unaudited financial results for the period ending September 30, ...

Ascendis Pharma (ASND) has released an update. Ascendis Pharma reported a revenue of €57.8 million in Q3 2024, driven by product launches and ...

YORVIPATH launching in U.S. with product availability expected mid-January 2025; ex-U.S. YORVIPATH revenue of €8.5 million in ...

Ascendis Pharma (ASND) is scheduled to announce Q3 earnings results on Thursday, November 14th, after market close. The ...

The group was led by Casdin Capital, which surged 16 percent last month, according to an investor. This puts its share class that invests only in public securities up more than 40 percent for the year ...

Adults with hypoparathyroidism treated with TransCon PTH in the phase 3 PaTHway open-label trial extension demonstrated ...

Wegovy manufacturer Ascendis Pharma has been tasked with supporting the development of a once-monthly GLP-1 drug.

Aristotle Atlantic Partners, LLC, an investment advisor, released its “Large Cap Growth Strategy” third quarter 2024 investor ...

Ascendis Pharma and Novo Nordisk announced a partnership to develop cardiovascular and metabolic drugs that utilize Ascendis’ ...

Plus: How AI can help cancer patients avoid unnecessary chemotherapies and make it easier to understand your dental X-rays.